

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Single Technology Appraisal (STA)

Gefitinib for the first-line treatment of locally advanced or metastatic non small cell lung cancer

Final matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> • AstraZeneca (gefitinib) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Afiya Trust • Age Concern England • Black Health Agency • Breathe Easy • British Lung Foundation • CANCERactive • Cancer Black Care • Cancer Equality • Cancer Voices • Chinese National Healthy Living Centre • Confederation of Indian Organisations • Counsel and Care • Equalities National Council • Helen Rollason Heal Cancer Charity • Help the Aged • Macmillan Cancer Support • Maggie's Centres • Marie Curie Cancer Care • Muslim Council of Great Britain • Muslim Health Network • National Cancer Alliance • National Council for Palliative Care • Roy Castle Lung Cancer Foundation • South Asian Health Foundation • Specialised Healthcare Alliance • Sue Ryder Care • Tenovus Cancer Information Centre 	<p><u>General</u></p> <ul style="list-style-type: none"> • Age Concern Cymru • Board of Community Health Councils in Wales • British National Formulary • Cancer Care Cymru • Department of Health, Social Services and Public Safety for Northern Ireland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Public Health Service for Wales • NHS Alliance • NHS Confederation • NHS Purchasing and Supply Agency • NHS Quality Improvement Scotland • Scottish Medicines Consortium <p><u>Comparator manufacturers</u></p> <ul style="list-style-type: none"> • Abraxis Bioscience (paclitaxel) • Actavis Pharmaceuticals (paclitaxel, vinorelbine) • Bristol Myers Squibb (carboplatin, paclitaxel) • Eli Lilly (gemcitabine, pemetrexed) • Hospira (carboplatin, cisplatin, vinorelbine, paclitaxel) • Medac (paclitaxel, vinorelbine) • Pierre Fabre (vinorelbine) • Pharmacia (cisplatin) • Sanofi Aventis (docetaxel)

National Institute for Health and Clinical Excellence

Final matrix for consultation on the appraisal of gefitinib for the first line treatment of locally advanced or metastatic non small cell lung cancer

Issue date: July 2009

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • United Kingdom Lung Cancer Coalition <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Cancer Physicians • Association of Respiratory Nurse Specialists • British Association for Services to the Elderly • British Geriatrics Society • British Oncological Association (BOA) • British Oncology Pharmacy Association • British Psychosocial Oncology Society • British Thoracic Society (Lung Cancer and Mesothelioma Working party) • Cancer Networks Pharmacists Forum • Cancer Research UK • General Practice Airways Group • National Lung Cancer Forum for Nurses • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians, Medical Oncology Joint Special Committee • Royal College of Radiologists • Royal Pharmaceutical Society • Royal Society of Medicine – Intellectual Disabilities Forum • United Kingdom Clinical Pharmacy Association • United Kingdom Oncology Nursing Society <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • Kirklees PCT • South Gloucestershire PCT • Welsh Assembly Government 	<p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • British Thoracic Oncology Group • Institute of Cancer Research • MRC CTU - Lung Cancer and Mesothelioma Group • National Cancer Research Institute • National Cancer Research Network • National Institute for Health Research • Policy Research Institute on Ageing and Ethnicity • Research Institute for the Care of Older People <p><u>Evidence Review Group</u></p> <ul style="list-style-type: none"> • Liverpool Reviews & Implementation Group, University of Liverpool • National Institute for Health Research Health Technology Assessment Programme <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> • National Collaborating Centre for Cancer <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • None

NICE is committed to promoting equality and eliminating unlawful discrimination.
Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*).

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Evidence Review Group

An independent academic group commissioned by the National Institute for Health Research Health Technology Assessment Programme to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.